2 results about "Anti-emetic" patented technology

This invention provides a method for treating postoperative nausea and vomiting using buccal acupuncture combined with a triple antiemetic regimen. The method employs a combined intervention of buccal acupuncture and a triple antiemetic regimen. The triple regimen consists of a 5-HT3 receptor antagonist, a glucocorticoid, and a dopamine receptor antagonist, administered intravenously in two separate doses. The buccal acupuncture uses CA-2 (upper jiao), CA-3 (middle jiao), and CA-4 (lower jiao) as core acupoints, with auxiliary and reinforcing acupoints added based on the surgical site and high-risk groups. A standardized procedure of pecking stimulation is applied, along with a corresponding postoperative remedial antiemetic medication regimen. This invention organically combines multi-target drug blockade with buccal acupuncture's visceral regulation, synergistically enhancing the antiemetic effect, reducing the incidence of nausea and vomiting, and decreasing the need for remedial medication. The regimen is highly standardized, widely adaptable, and can meet the postoperative nausea and vomiting control needs of various surgeries and high-risk groups. It exhibits good safety, strong repeatability, and high clinical application value.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors in combination with a Compound of Formula VIII or a Compound of Formula IX, as described herein, or in combination with an antiemetic agent, such as an antipsychotic agent, e.g., olanzapine, for preventing or treating nausea and / or vomiting, e.g., CINV (chemotherapy-induced nausea and vomiting). In some embodiments, the Compound of Formula VIII or the Compound of Formula IX is used as mono-therapy (i.e., without a PDE1 inhibitor).